Frequency of antiepileptic drugs and response change in pediatric patients receiving 2 or more antiepileptic drugs

References

1. ↵
   1. Bashiri FA

   (2017) Childhood epilepsies: What should a pediatrician know? Neurosciences (Riyadh) 22, 14–19.
2. ↵
   1. Naimo GD,
   2. Guarnaccia M,
   3. Sprovieri T,
   4. Ungaro C,
   5. Conforti FL,
   6. Andò S,
   7. et al.

   (2019) A Systems Biology Approach for Personalized Medicine in Refractory Epilepsy. Int J Mol Sci 20, E3717.
3. ↵
   1. Russo A,
   2. Posar A,
   3. Conti S,
   4. Parmeggiani A

   (2015) Prognostic factors of drug-resistant epilepsy in childhood: An Italian study. Pediatr Int 57, 1143–1148.
4. ↵
   1. Verrotti A,
   2. Tambucci R,
   3. Di Francesco L,
   4. Pavone P,
   5. Iapadre G,
   6. Altobelli E,
   7. et al.

   (2020) The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection. Expert Rev Neurother 20, 167–173.
5. ↵
   1. Park KM,
   2. Kim SE,
   3. Lee BI

   (2019) Antiepileptic Drug Therapy in Patients with Drug-Resistant Epilepsy. J Epilepsy Res 9, 14–26.
6. ↵
   1. Joshi R,
   2. Tripathi M,
   3. Gupta P,
   4. Gulati S,
   5. Gupta YK

   (2017) Adverse effects & drug load of antiepileptic drugs in patients with epilepsy: Monotherapy versus polytherapy. Indian J Med Res 145, 317–326.
7. ↵
   1. Martínez-Lizana E,
   2. Gil-Lopez F,
   3. Donaire A,
   4. Aparicio J,
   5. Brandt A,
   6. Carreño M

   (2017) Outcome of treatment changes in patients with drug-resistant chronic epilepsy: A tertiary center experience. Epilepsy Res 136, 97–102.
8. ↵
   1. Nair DR

   (2016) Management of Drug-Resistant Epilepsy. Continuum (Minneapolis, MN, USA) 22, 157–172.
9. ↵
   1. Plevin D,
   2. Jureidini J,
   3. Howell S,
   4. Smith N

   (2018) Paediatric antiepileptic polytherapy: systematicreview of efficacy and neurobehavioural effects and a tertiary centre experience. Acta Paediatr.
10. ↵
    1. Egunsola O,
    2. Choonara I,
    3. Sammons HM,
    4. Whitehouse WP

    (2018) Safety of antiepileptic drugs in children and young people: A prospective cohort study. Seizure 56, 20–25.
11. ↵
    1. Albsoul-Younes A,
    2. Gharaibeh L,
    3. Murtaja AA,
    4. Masri A,
    5. Alabbadi I,
    6. Al-Qudah AA

    (2016) Patterns of antiepileptic drugs used in epileptic pediatric patients in Jordan. Neurosciences (Riyadh) 21, 264–267.
12. ↵
    1. Al-Qudah AA,
    2. Albsoul-Younes A,
    3. Masri AT,
    4. AbuRahmah SK,
    5. Alabadi IA,
    6. Nafi OA,
    7. et al.

    (2017) Type and etiology of pediatric epilepsy in Jordan. A multicenter study. Neurosciences (Riyadh) 22, 267–273.
13. ↵
    1. Fisher RS,
    2. Cross JH,
    3. French JA,
    4. Higurashi N,
    5. Hirsch E,
    6. Jansen FE,
    7. et al.

    (2017) Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia 58, 522–530.
14. ↵
    1. Camfield PR,
    2. Camfield CS

    (2017) Intractable seizures after a lengthy remission in childhood-onset epilepsy. Epilepsia 58, 2048–2052.
15. ↵
    1. Syvertsen M,
    2. Nakken KO,
    3. Edland A,
    4. Hansen G,
    5. Hellum MK,
    6. Koht J

    (2015) Prevalence and etiology of epilepsy in a Norwegian county: A population based study. Epilepsia 56, 699–706.
16. ↵
    1. Sirven JI,
    2. Noe K,
    3. Hoerth M,
    4. Drazkowski J

    (2012) Antiepileptic drugs 2012: Recent advances and trends. Mayo Clin Proc 87, 879–889.
17. ↵
    1. Lacy CF,
    2. Armstrong LL,
    3. Goldman MP,
    4. Lance LL

    , eds, editors. Drug Information Handbook: A Comprehensive Resource for All Clinicians and Healthcare Professionals (Lexi Comp’s Drug Information Handbooks). 15th Edition. Hudson (Ohio): Lexi-Comp Inc, 2013.
18. ↵
    1. Moosa ANV

    (2019) Antiepileptic Drug Treatment of Epilepsy in Children. Continuum (Minneap Minn) 25, 381–407.
19. ↵
    1. O’Rourke G,
    2. O’Brien JJ

    (2017) Identifying the barriers to antiepileptic drug adherence among adults with epilepsy. Seizure 45, 160–168.
20. ↵
    1. Fishman J,
    2. Kalilani L,
    3. Song Y,
    4. Swallow E,
    5. Wild I

    (2018) Antiepileptic Drug Titration and Related Health Care Resource Use and Costs. J Manag Care Spec Pharm 24, 929–938.
21. ↵
    1. Gupte-Singh K,
    2. Wilson JP,
    3. Barner JC,
    4. Richards KM,
    5. Rascati KL,
    6. Hovinga C

    (2018) Patterns of antiepileptic drug use in patients with potential refractory epilepsy in Texas Medicaid. Epilepsy Behav 87, 108–116.